Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17960227 | 0.87 | TSHR (0.43) | HSD17B10RIPK1HDAC6HDAC8HDAC1 | |
| SCHEMBL17960114 | 0.87 | CHRM1 (0.49) | RIPK1HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17960345 | 0.85 | HDAC6 (0.46) | RIPK1HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17960645 | 0.85 | HDAC6 (0.46) | RIPK1HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17960343 | 0.85 | HDAC6 (0.46) | RIPK1HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17960446 | 0.84 | ALDH1A1 (0.49) | HPGDRIPK1HDAC6HDAC8HDAC1 | |
| SCHEMBL17960499 | 0.82 | USP9X (0.46) | RIPK1HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17960712 | 0.82 | HSD17B10 (0.49) | HSD17B10HPGDRIPK1HDAC6HDAC1 | |
| SCHEMBL17973717 | 0.81 | RIPK1 (0.46) | RIPK1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17960273 | 0.81 | ALDH1A1 (0.49) | HSD17B10RIPK1HDAC6HDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | claimed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | claimed |
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2022-11-17 | — | — | US | disclosed |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10464909-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464910-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464909-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464910-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10457652-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190119228-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119228-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119229-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119229-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119228-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-10464910-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-10457652-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-20190119229-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-10464909-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | ALOX15 2987/4885HSD17B10 456/4885HPGD 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.